Help your patients move toward symptom control with once-daily AUSTEDO XR1

Get your patients started with 4-week Titration Kits, which were evaluated in a real-world study2*

  • ~80% of patients reached ≥24 mg/day by Week 4
  • 97% of patients adhered to Titration Kit
  • Patients and physicians reported treatment success consistent with the pivotal studies

Patients in the study used the AUSTEDO BID 4-week Titration Kit.

AUSTEDO XR 4-week Titration Kit.

Two ways to get patients started with the 4-week Titration Kit:

Sample with Titration Kit
And prescribe 36 mg/day for Week 51

Blister packs for AUSTEDO XR 4-week Titration Kit.

(ask your sales representative for 4-week Titration Kit samples)

Prescribe Titration Kit (NDC: 68546-490-52)
And use 30-day Free Trial Voucher§

AUSTEDO XR 4-week Titration Kit and 30-day Free Trial Voucher for new patients. This Free Trial Voucher is not conditioned on any past, present, or future purchase, including refills. No purchase is required.
Blister packs for AUSTEDO XR 4-week Titration Kit.

(prescription should not include refills; provide a separate prescription for maintenance dose)

Continue titrating weekly until symptom control is effectively and tolerably achieved (48 mg/day maximum dosage).1

For continuing patients:

Write once-daily AUSTEDO XR for their next refill (at same total daily dose as AUSTEDO BID)1

Insurance codes

ICD-10 code:   

G24.01 Tardive Dyskinesia (TD)

NDC codes:    

6 mg: 68546-0470-56   |   12 mg: 68546-0471-56   |   24 mg: 68546-0472-56   |   
Titration Kit: 68546-490-52

Teva Shared Solutions®.

Use the Prescription & Service Request Form (PSRF) to get started with the support of Teva Shared Solutions®

Financial assistance offerings available: some
patients may pay $10 or less per month for AUSTEDO2

Learn more about cost and coverage

Additional resources to help with patient access:

*The START study was a non-interventional, real-world study assessing 4-week Titration Kit utilization and treatment success in 50 patients of similar demographics to the AUSTEDO tardive dyskinesia pivotal studies.2

Based on Patient Global Impression of Change and Clinical Global Impression of Change.2

Notify pharmacy if patient has been sampled.

§Request pharmacy apply 30-day Free Trial Voucher against initial 30-day Rx. Certain restrictions apply. Terms and conditions on

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.